Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO
2022-503011-42-00Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Roflumilast with Placebo (2 arms). Primary endpoint: HECSI75 response at week 16. Started Sep 2023; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2022-503011-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503011-42-00.